ixekizumab vs netakimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriatic Arthritis
Shared mechanism: IL-17 · full Psoriatic Arthritis pipeline
ixekizumab · Taltz
Marketed by Eli Lilly and partners
NCT01695239 · Phase 3 · completed
This randomized, quadruple-blind, placebo- and active-comparator-controlled trial in 417 people with active psoriatic arthritis measured ACR20 response at week 24 as its primary endpoint. Both ixekizumab doses clearly outperformed placebo (57.9% and 62.1% vs 30.2%, p<0.001), and the active comparator adalimumab also beat placebo, confirming the trial could detect a true effect.
Next expected readout: February 2028 · NCT07443956 (registry estimate)
Reported efficacy
Percentage of Participants Achieving American College of Rheumatology 20 Index (ACR20) (Week 24): ACR20 response at week 24 (SPIRIT-P2): placebo 23/118 (20%) vs ixekizumab Q4W 65/122 (53%), effect size 33.8% (95% CI 22.4-45.2), p<0.0001; vs ixekizumab Q2W 59/123 (48%), effect size 28.5% (95% CI 17.1-39.8), p<0.0001 (met)
Result source: NCT02349295
netakimab
Marketed by Biocad
NCT03598751 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial of 194 patients. The proportion of patients achieving a validated joint-response measure (ACR20) was overwhelmingly higher with netakimab than placebo, a gap large enough to leave no real doubt about the direction of the effect even though a formal statistical test was not reported in the source used.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Reported efficacy
ACR 20 (week 24): ACR20 response at week 24: 82% (80/97) netakimab vs 9% (9/97) placebo. (met)
Result source: NCT03598751
Results for Psoriatic Arthritis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | ixekizumab | netakimab |
|---|---|---|
| ACR20 | 53.3% vs 19.5%+33.8 vs placeboNCT023492957 other results
| 82% vs 9%a+73 vs placeboNCT03598751 |
| ACR50 | 35.2% vs 5.1%+30.1 vs placeboNCT023492954 other results
| —Not posted · NCT03598751 |
| PASI 75 | 57.4% vs 10.4%+47 vs placeboNCT023492951 other result
| —Not posted · NCT03598751 |
| Minimal disease activity | 27.9% vs 3.4%+24.5 vs placeboNCT023492951 other result
| —Not posted · NCT03598751 |
| HAQ-DI, change | -0.6 vs -0.2−0.4 vs placeboNCT023492955 other results
| —Not posted · NCT03598751 |
ACR20
- ixekizumab
- 53.3% vs 19.5%+33.8 vs placeboNCT02349295
7 other results
- 48% vs 19.5% NCT02349295
- 57.9% vs 30.2% NCT01695239
- 62.1% vs 30.2% NCT01695239
- 50% vs 22% NCT02349295
- 48% vs 22% NCT02349295
- 57% vs 31.1% NCT01695239
- 60.2% vs 31.1% NCT01695239
- netakimab
- 82% vs 9%a+73 vs placeboNCT03598751
ACR50
- ixekizumab
- 35.2% vs 5.1%+30.1 vs placeboNCT02349295
4 other results
- 33.3% vs 5.1% NCT02349295
- 40.2% vs 15.1% NCT01695239
- 46.6% vs 15.1% NCT01695239
- 50.5% vs 46.6% NCT03151551
- netakimab
- —Not posted · NCT03598751
PASI 75
- ixekizumab
- 57.4% vs 10.4%+47 vs placeboNCT02349295
1 other result
- 61.8% vs 10.4% NCT02349295
- netakimab
- —Not posted · NCT03598751
Minimal disease activity
- ixekizumab
- 27.9% vs 3.4%+24.5 vs placeboNCT02349295
1 other result
- 23.6% vs 3.4% NCT02349295
- netakimab
- —Not posted · NCT03598751
HAQ-DI, change
- ixekizumab
- -0.6 vs -0.2−0.4 vs placeboNCT02349295
5 other results
- -0.4 vs -0.2 NCT02349295
- -0.4 vs -0.2 NCT01695239
- -0.5 vs -0.2 NCT01695239
- -0.8 vs -0.7 NCT02584855
- -0.7 vs -0.6 NCT03151551
- netakimab
- —Not posted · NCT03598751
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. ixekizumab: 4 of 4 rows · netakimab: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | ixekizumab | netakimab |
|---|---|---|
| Dropout rate | —Q2Wa NCT01695239 · Phase 3 show 22 more results—Q4W NCT01695239 · Phase 3 6.8%Q2W NCT01695239 · Phase 3 9.3%Q4W NCT01695239 · Phase 3 —Q2W NCT01695239 · Phase 3 —Q4W NCT01695239 · Phase 3 —80 mg Q4W NCT02349295 · Phase 3 —80 mg Q4W NCT02349295 · Phase 3 9%80 mg Q4W NCT02349295 · Phase 3 —80 mg Q2W NCT02349295 · Phase 3 —80 mg Q2W NCT02349295 · Phase 3 11.4%80 mg Q2W NCT02349295 · Phase 3 6%Ixekizumab - Active PsA NCT05855967 · Phase 4 · registry result, not featured evidence 6%Ixekizumab - PsO With no Active Ps NCT05855967 · Phase 4 · registry result, not featured evidence —Q2W/Q4W NCT05855967 · Phase 4 · registry result, not featured evidence —Q4W NCT05855967 · Phase 4 · registry result, not featured evidence 6.4%Ixekizumab NCT03151551 · Phase 4 · registry result, not featured evidence —Ixekizumab Follow-up NCT03151551 · Phase 4 · registry result, not featured evidence —80 mg every 2 weeks NCT02584855 · Phase 3 · registry result, not featured evidence —80 mg every 2 weeks NCT02584855 · Phase 3 · registry result, not featured evidence —80 mg every 2 weeks NCT02584855 · Phase 3 · registry result, not featured evidence —Ixekizumab NCT02584855 · Phase 3 · registry result, not featured evidence 26.1%Ixekizumab Open Label NCT02584855 · Phase 3 · registry result, not featured evidence | — |
| Discontinued due to AEs | —Q2Wa NCT01695239 · Phase 3 show 22 more results—Q4W NCT01695239 · Phase 3 2.9%Q2W NCT01695239 · Phase 3 1.9%Q4W NCT01695239 · Phase 3 —Q2W NCT01695239 · Phase 3 —Q4W NCT01695239 · Phase 3 —80 mg Q4W NCT02349295 · Phase 3 —80 mg Q4W NCT02349295 · Phase 3 4.1%80 mg Q4W NCT02349295 · Phase 3 —80 mg Q2W NCT02349295 · Phase 3 —80 mg Q2W NCT02349295 · Phase 3 5.7%80 mg Q2W NCT02349295 · Phase 3 —Ixekizumab - Active PsA NCT05855967 · Phase 4 · registry result, not featured evidence —Ixekizumab - PsO With no Active Ps NCT05855967 · Phase 4 · registry result, not featured evidence —Q2W/Q4W NCT05855967 · Phase 4 · registry result, not featured evidence —Q4W NCT05855967 · Phase 4 · registry result, not featured evidence 0%Ixekizumab NCT03151551 · Phase 4 · registry result, not featured evidence —Ixekizumab Follow-up NCT03151551 · Phase 4 · registry result, not featured evidence —80 mg every 2 weeks NCT02584855 · Phase 3 · registry result, not featured evidence —80 mg every 2 weeks NCT02584855 · Phase 3 · registry result, not featured evidence —80 mg every 2 weeks NCT02584855 · Phase 3 · registry result, not featured evidence —Ixekizumab NCT02584855 · Phase 3 · registry result, not featured evidence 3.6%Ixekizumab Open Label NCT02584855 · Phase 3 · registry result, not featured evidence | — |
| Serious AEs | 0%Q2Wa NCT01695239 · Phase 3 show 22 more results0%Q4W NCT01695239 · Phase 3 10.4%Q2W NCT01695239 · Phase 3 15%Q4W NCT01695239 · Phase 3 5.6%Q2W NCT01695239 · Phase 3 2.9%Q4W NCT01695239 · Phase 3 0%80 mg Q4W NCT02349295 · Phase 3 11.7%80 mg Q4W NCT02349295 · Phase 3 2.5%80 mg Q4W NCT02349295 · Phase 3 0%80 mg Q2W NCT02349295 · Phase 3 9.3%80 mg Q2W NCT02349295 · Phase 3 6.5%80 mg Q2W NCT02349295 · Phase 3 —Ixekizumab - Active PsA NCT05855967 · Phase 4 · registry result, not featured evidence —Ixekizumab - PsO With no Active Ps NCT05855967 · Phase 4 · registry result, not featured evidence 0.5%Q2W/Q4W NCT05855967 · Phase 4 · registry result, not featured evidence 0%Q4W NCT05855967 · Phase 4 · registry result, not featured evidence 4.2%Ixekizumab NCT03151551 · Phase 4 · registry result, not featured evidence 2.6%Ixekizumab Follow-up NCT03151551 · Phase 4 · registry result, not featured evidence 4.5%80 mg every 2 weeks NCT02584855 · Phase 3 · registry result, not featured evidence 1.1%80 mg every 2 weeks NCT02584855 · Phase 3 · registry result, not featured evidence 1%80 mg every 2 weeks NCT02584855 · Phase 3 · registry result, not featured evidence 1.3%Ixekizumab NCT02584855 · Phase 3 · registry result, not featured evidence 5.1%Ixekizumab Open Label NCT02584855 · Phase 3 · registry result, not featured evidence | — |
| Most frequent reported AEs | Q2Wa back pain 0% (placebo 0%) bronchitis 0% (placebo 2.8%) injection site erythema 0% (placebo 0%) NCT01695239 · Phase 3 show 20 more resultsQ4W back pain 0% (placebo 0%) bronchitis 0% (placebo 2.8%) injection site erythema 0% (placebo 0%) NCT01695239 · Phase 3 Q2W viral upper respiratory tract infection 11.5% (placebo 4.7%) upper respiratory tract infection 9.8% (placebo 6.6%) injection site reaction 7.1% (placebo 0%) NCT01695239 · Phase 3 Q4W upper respiratory tract infection 11.2% (placebo 6.6%) viral upper respiratory tract infection 11.2% (placebo 4.7%) injection site reaction 6.4% (placebo 0%) NCT01695239 · Phase 3 Q2W injection site reaction 12.1% (placebo 0%) injection site erythema 6.5% (placebo 0%) viral upper respiratory tract infection 5.6% (placebo 4.7%) NCT01695239 · Phase 3 Q4W injection site reaction 15.7% (placebo 0%) injection site erythema 12.7% (placebo 0%) bronchitis 2.9% (placebo 2.8%) NCT01695239 · Phase 3 80 mg Q4W ear infection 6.7% (placebo 0.8%) goitre 6.7% (placebo 0%) hepatic steatosis 6.7% (placebo 0.8%) NCT02349295 · Phase 3 80 mg Q4W nasopharyngitis 18% (placebo 3.4%) upper respiratory tract infection 13.5% (placebo 7.6%) bronchitis 9.9% (placebo 3.4%) NCT02349295 · Phase 3 80 mg Q4W upper respiratory tract infection 9.8% (placebo 7.6%) nasopharyngitis 7.4% (placebo 3.4%) oropharyngeal pain 5.7% (placebo 0%) NCT02349295 · Phase 3 80 mg Q2W injection site pain 11.8% (placebo 1.7%) injection site reaction 11.8% (placebo 0.8%) vulvovaginal candidiasis 8.3% (placebo 0%) NCT02349295 · Phase 3 80 mg Q2W upper respiratory tract infection 18.7% (placebo 7.6%) nasopharyngitis 14% (placebo 3.4%) bronchitis 10.3% (placebo 3.4%) NCT02349295 · Phase 3 80 mg Q2W injection site reaction 12.2% (placebo 0.8%) upper respiratory tract infection 9.8% (placebo 7.6%) hypertension 4.9% (placebo 2.5%) NCT02349295 · Phase 3 Q2W/Q4W latent tuberculosis 8.6% pyrexia 8.6% injection site erythema 1.9% NCT05855967 · Phase 4 · registry result, not featured evidence Q4W latent tuberculosis 9.8% urinary tract infection 4.9% c-reactive protein increased 2.4% NCT05855967 · Phase 4 · registry result, not featured evidence nasopharyngitis 13.4% upper respiratory tract infection 6.4% injection site reaction 5.7% NCT03151551 · Phase 4 · registry result, not featured evidence nasopharyngitis 1.9% upper respiratory tract infection 1.1% injection site reaction 0% NCT03151551 · Phase 4 · registry result, not featured evidence 80 mg every 2 weeks nasopharyngitis 14.3% (placebo 5.1%) upper respiratory tract infection 9% (placebo 5.1%) bronchitis 3.8% (placebo 1.3%) NCT02584855 · Phase 3 · registry result, not featured evidence 80 mg every 2 weeks upper respiratory tract infection 2.3% (placebo 5.1%) psoriasis 1.1% (placebo 5.1%) alanine aminotransferase increased 0.8% (placebo 1.3%) NCT02584855 · Phase 3 · registry result, not featured evidence 80 mg every 2 weeks nasopharyngitis 13.4% (placebo 5.1%) upper respiratory tract infection 9.3% (placebo 5.1%) injection site reaction 7.2% (placebo 0%) NCT02584855 · Phase 3 · registry result, not featured evidence nasopharyngitis 13.9% (placebo 5.1%) upper respiratory tract infection 11.4% (placebo 5.1%) uterine leiomyoma 6.3% (placebo 0%) NCT02584855 · Phase 3 · registry result, not featured evidence injection site reaction 15% (placebo 0%) upper respiratory tract infection 12.4% (placebo 5.1%) nasopharyngitis 8.6% (placebo 5.1%) NCT02584855 · Phase 3 · registry result, not featured evidence | — |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
ixekizumab
show 4 more results
show 3 more results
show 5 more results
show 1 more result
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 6 more results
show 4 more results
show 1 more result
show 1 more result
+ 44 further endpoints in the CSV export.
Psoriasis
Shared mechanism: IL-17 · full Psoriasis pipeline
ixekizumab · Taltz
Marketed by Eli Lilly and partners
NCT01474512 · Phase 3 · completed
The study was randomized, quadruple-blind, placebo-controlled, and included 1,296 participants. Its clinical primary endpoints, sPGA 0/1 and PASI75 at Week 12, were met for both ixekizumab regimens versus placebo, with p<0.001 for each comparison.
Next expected readout: December 2027 · NCT04537689 (registry estimate)
Reported efficacy
Percentage of Participants Achieving American College of Rheumatology 20 (ACR20) Response at Week 24 (Efficacy of Ixekizumab in Participants With Active Psoriatic Arthritis. Measure: American College of Rheumatology 20 Index [ACR20]): ACR20 response at week 24 (SPIRIT-P1): ixekizumab Q2W 62.1%, ixekizumab Q4W 57.9%, placebo 30.2% — significantly more responders in both ixekizumab arms than placebo. (met)
Result source: NCT01695239
netakimab
Marketed by Biocad
NCT03390101 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial with 213 participants and a clinical psoriasis endpoint (PASI 75) assessed at week 12. Results were not posted at the time of grading; the key result shown was recorded subsequently from the registry record.
Reported efficacy
• The Proportion (Number) of Patients in Each Study Arm Who Achieved a PASI 75 at Week 12 of Treatment: • The Proportion (Number) of Patients in Each Study Arm Who Achieved a PASI 75 at Week 12 of Treatment (week 12): BCD-085 Q2W 66/85 (77.6%) | BCD-085 Q4W 70/84 (83.3%) vs Placebo 0/44 (0.0%) (met)
Result source: NCT03390101
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | ixekizumab | netakimab |
|---|---|---|
| PASI 75 | 84.2% vs 7.3%+76.9 vs placeboNCT0164617716 other results
| 77.6% vs 0%+77.6 vs placeboNCT033901014 other results
|
| PASI 90 | 72.8% vs 42.2%vs UstekinumabNCT025618069 other results
| —Not posted · NCT07008547 |
| PASI 100 | 35% vs 0%+35 vs placeboNCT0164617710 other results
| —Not posted · NCT07008547 |
| sPGA 0/1 | 75.4% vs 6.7%+68.7 vs placeboNCT0164617716 other results
| —Not posted · NCT07008547 |
| DLQI, change | -9.6 vs -1.7−7.9 vs placeboNCT0164617712 other results
| —Not posted · NCT07008547 |
PASI 75
- ixekizumab
- 84.2% vs 7.3%+76.9 vs placeboNCT01646177
16 other results
- 87.3% vs 7.3% NCT01646177
- 87.4% vs 8% NCT03364309
- 93.8% vs 8% NCT03364309
- 82.6% vs 3.9% NCT01474512
- 89.1% vs 3.9% NCT01474512
- 77.5% vs 2.4% NCT01597245
- 89.7% vs 2.4% NCT01597245
- 88.7% vs 25% NCT03073200
- 53.9% vs 8.9% NCT03073200
- 84.2% vs 26.3% NCT03073200
- 88.2% vs 68.7% NCT02561806
- 82.1% vs 7.7% NCT01107457
- 82.8% vs 7.7% NCT01107457
- 76.7% vs 7.7% NCT01107457
- 28.6% vs 7.7% NCT01107457
- 22.9% vs 5.1% NCT03573323
- netakimab
- 77.6% vs 0%+77.6 vs placeboNCT03390101
4 other results
- 83.3% vs 0% NCT03390101
- 92.9% vs 23.1% NCT02762994
- 83.3% vs 23.1% NCT02762994
- 80% vs 23.1% NCT02762994
PASI 90
- ixekizumab
- 72.8% vs 42.2%vs UstekinumabNCT02561806
9 other results
- 65.3% vs 3.1% NCT01646177
- 68.1% vs 3.1% NCT01646177
- 75.9% vs 2.3% NCT03364309
- 82.4% vs 2.3% NCT03364309
- 59.7% vs 0.6% NCT01597245
- 70.7% vs 0.6% NCT01597245
- 78.3% vs 5.4% NCT03073200
- 58.5% vs 35.9% NCT03573323
- 21% vs 7.9% NCT03573323
- netakimab
- —Not posted · NCT07008547
PASI 100
- ixekizumab
- 35% vs 0%+35 vs placeboNCT01646177
10 other results
- 37.7% vs 0% NCT01646177
- 29.3% vs 0% NCT03364309
- 33% vs 0% NCT03364309
- 30.8% vs 0.6% NCT01597245
- 40.5% vs 0.6% NCT01597245
- 49.6% vs 1.8% NCT03073200
- 36% vs 14.5% NCT02561806
- 41.3% vs 24.9% NCT03573323
- 29.6% vs 13.6% NCT03573323
- 6.7% vs 1.4% NCT03573323
- netakimab
- —Not posted · NCT07008547
sPGA 0/1
- ixekizumab
- 75.4% vs 6.7%+68.7 vs placeboNCT01646177
16 other results
- 80.5% vs 6.7% NCT01646177
- 79.9% vs 3.4% NCT03364309
- 86.4% vs 3.4% NCT03364309
- 76.4% vs 3.2% NCT01474512
- 81.8% vs 3.2% NCT01474512
- 72.9% vs 2.4% NCT01597245
- 83.2% vs 2.4% NCT01597245
- 80.9% vs 10.7% NCT03073200
- 73.3% vs 2.7% NCT02718898
- 47.8% vs 7.1% NCT03073200
- 76.3% vs 5.3% NCT03073200
- 83.6% vs 57.2% NCT02561806
- 71.4% vs 7.7% NCT01107457
- 72.4% vs 7.7% NCT01107457
- 70% vs 7.7% NCT01107457
- 25% vs 7.7% NCT01107457
- netakimab
- —Not posted · NCT07008547
DLQI, change
- ixekizumab
- -9.6 vs -1.7−7.9 vs placeboNCT01646177
12 other results
- -10.2 vs -1.7 NCT01646177
- -8.6 vs 0.9 NCT03364309
- -8.9 vs 0.9 NCT03364309
- -10.7 vs -1 NCT01474512
- -11.1 vs -1 NCT01474512
- -9.4 vs -2 NCT01597245
- -10.4 vs -2 NCT01597245
- -9.7 vs -1.4 NCT02718898
- -8.2 vs -1.2 NCT01107457
- -8.4 vs -1.2 NCT01107457
- -6.6 vs -1.2 NCT01107457
- -6.3 vs -1.2 NCT01107457
- netakimab
- —Not posted · NCT07008547
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. ixekizumab: 4 of 4 rows · netakimab: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | ixekizumab | netakimab |
|---|---|---|
| Dropout rate | —Ixe Long-Term Extensiona NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 show 93 more results4.2%Q2W NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 5.6%Q4W NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 —Q4W NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 —Q4W NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 —Q12W NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 —Q4W NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 —Placebo Long-Term Extension NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 —Q4W NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 —Q4W NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 —Total Ixe Long-Term Extension NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 —Q4W NCT01597245 · Phase 3 · Psoriasis · phase 3 —Ixe Long-Term Extension NCT01597245 · Phase 3 · Psoriasis · phase 3 2.6%Q2W NCT01597245 · Phase 3 · Psoriasis · phase 3 —Q4W NCT01597245 · Phase 3 · Psoriasis · phase 3 5.5%Q4W NCT01597245 · Phase 3 · Psoriasis · phase 3 —Q4W NCT01597245 · Phase 3 · Psoriasis · phase 3 —Q4W NCT01597245 · Phase 3 · Psoriasis · phase 3 —ETN/IXEQ4W (Maintenance Period) NCT03073200 · Phase 3 —ETN/IXEQ4W/IXEQ4W (Extension Perio NCT03073200 · Phase 3 0.9%IXEQ4W (Double-Blinded Treatment P NCT03073200 · Phase 3 —IXEQ4W (Randomized Withdrawal Peri NCT03073200 · Phase 3 —IXEQ4W/IXEQ4W (Maintenance Period) NCT03073200 · Phase 3 —IXEQ4W/IXEQ4W/IXEQ4W (Extension Pe NCT03073200 · Phase 3 —IXEQ4W_Re-Treatment (Randomized Wi NCT03073200 · Phase 3 —PBO/IXEQ4W (Maintenance Period) NCT03073200 · Phase 3 —PBO/IXEQ4W/IXEQ4W (Extension Perio NCT03073200 · Phase 3 —Q2W NCT01695239 · Phase 3 —Q4W NCT01695239 · Phase 3 6.8%Q2W NCT01695239 · Phase 3 9.3%Q4W NCT01695239 · Phase 3 —Q2W NCT01695239 · Phase 3 —Q4W NCT01695239 · Phase 3 5.7%80 mg every 2 weeks NCT01646177 · Phase 3 6.7%80 mg every 4 weeks NCT01646177 · Phase 3 6%Ixekizumab - Active PsA NCT05855967 · Phase 4 · registry result, not featured evidence 6%Ixekizumab - PsO With no Active Ps NCT05855967 · Phase 4 · registry result, not featured evidence —Q2W/Q4W NCT05855967 · Phase 4 · registry result, not featured evidence —Q4W NCT05855967 · Phase 4 · registry result, not featured evidence 20%Ixekizumab - Erythrodermic Psorias NCT03942042 · Phase 4 · registry result, not featured evidence 14.3%Ixekizumab - Generalized Pustular NCT03942042 · Phase 4 · registry result, not featured evidence 10.6% NCT03573323 · Phase 4 · registry result, not featured evidence —80 mg Q2W NCT03364309 · Phase 3 · registry result, not featured evidence —80 mg Q2W NCT03364309 · Phase 3 · registry result, not featured evidence —80 mg Q2W NCT03364309 · Phase 3 · registry result, not featured evidence —80 mg Q2W NCT03364309 · Phase 3 · registry result, not featured evidence —80 mg Q2W NCT03364309 · Phase 3 · registry result, not featured evidence —80 mg Q2W NCT03364309 · Phase 3 · registry result, not featured evidence 0.6%80 mg Q2W NCT03364309 · Phase 3 · registry result, not featured evidence —80 mg Q4W NCT03364309 · Phase 3 · registry result, not featured evidence —80 mg Q4W NCT03364309 · Phase 3 · registry result, not featured evidence —80 mg Q4W NCT03364309 · Phase 3 · registry result, not featured evidence —80 mg Q4W NCT03364309 · Phase 3 · registry result, not featured evidence —80 mg Q4W NCT03364309 · Phase 3 · registry result, not featured evidence —80 mg Q4W NCT03364309 · Phase 3 · registry result, not featured evidence 2.3%80 mg Q4W NCT03364309 · Phase 3 · registry result, not featured evidence —80 mg Q2W NCT02718898 · Phase 3 · registry result, not featured evidence 7.4%Ixekizumab NCT02634801 · Phase 3 · registry result, not featured evidence —Ixekizumab-Extension Period NCT02634801 · Phase 3 · registry result, not featured evidence —Ixekizumab-Treatment Period NCT02634801 · Phase 3 · registry result, not featured evidence 3.7%Ixekizumab NCT02561806 · Phase 3 · registry result, not featured evidence —Ixekizumab - Induction NCT02561806 · Phase 3 · registry result, not featured evidence —Ixekizumab - Maintenance NCT02561806 · Phase 3 · registry result, not featured evidence —Ixekizumab - Post Treatment Follow NCT02561806 · Phase 3 · registry result, not featured evidence 1.1%80 mg NCT01624233 · Phase 3 · registry result, not featured evidence —80 mg NCT01624233 · Phase 3 · registry result, not featured evidence —80 mg NCT01624233 · Phase 3 · registry result, not featured evidence 12.1%80 mg Q2W NCT02513550 · Phase 3 · registry result, not featured evidence —80 mg Q2W NCT02513550 · Phase 3 · registry result, not featured evidence —80 mg Q2W NCT02513550 · Phase 3 · registry result, not featured evidence 11.6%80 mg Q4W NCT02513550 · Phase 3 · registry result, not featured evidence —80 mg Q4W NCT02513550 · Phase 3 · registry result, not featured evidence 12.4%80 mg Q4W/Q2W NCT02513550 · Phase 3 · registry result, not featured evidence —80 mg Q4W/Q2W NCT02513550 · Phase 3 · registry result, not featured evidence —80 mg Q4W/Q2W NCT02513550 · Phase 3 · registry result, not featured evidence —80 mg Q4W NCT02513550 · Phase 3 · registry result, not featured evidence —80 mg Q4W NCT02387801 · Phase 3 · registry result, not featured evidence 0%Q2W NCT02387801 · Phase 3 · registry result, not featured evidence —Q2W NCT02387801 · Phase 3 · registry result, not featured evidence 0%Q4W NCT02387801 · Phase 3 · registry result, not featured evidence —Q4W NCT02387801 · Phase 3 · registry result, not featured evidence —80 mg NCT01777191 · Phase 3 · registry result, not featured evidence 7.8%80 mg NCT01777191 · Phase 3 · registry result, not featured evidence —80 mg NCT01777191 · Phase 3 · registry result, not featured evidence 5.9%80 mg NCT01777191 · Phase 3 · registry result, not featured evidence —80 mg NCT01777191 · Phase 3 · registry result, not featured evidence 3.6%150 mg NCT01107457 · Phase 2 · registry result, not featured evidence 10.3%75 mg NCT01107457 · Phase 2 · registry result, not featured evidence 3.3%25 mg NCT01107457 · Phase 2 · registry result, not featured evidence 25%10 mg NCT01107457 · Phase 2 · registry result, not featured evidence —80mg Q2W Multiple Dose NCT03073213 · Phase 1 · registry result, not featured evidence —80mg Q4W Multiple Dose NCT03073213 · Phase 1 · registry result, not featured evidence 0%Single Dose NCT03073213 · Phase 1 · registry result, not featured evidence — NCT02993471 · Phase 1 · registry result, not featured evidence · combination | 0%Q2Wb NCT03390101 · Phase 3 · monotherapy · Psoriasis · phase 3 show 4 more results2.4%Q4W NCT03390101 · Phase 3 · monotherapy · Psoriasis · phase 3 6.7%120 mg NCT02762994 · Phase 2 · registry result, not featured evidence 3.2%80 mg NCT02762994 · Phase 2 · registry result, not featured evidence 3.2%40 mg NCT02762994 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —Ixe Long-Term Extensiona NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 show 93 more results2.3%Q2W NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 2.3%Q4W NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 —Q4W NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 —Q4W NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 —Q12W NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 —Q4W NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 —Placebo Long-Term Extension NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 —Q4W NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 —Q4W NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 —Total Ixe Long-Term Extension NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 —Q4W NCT01597245 · Phase 3 · Psoriasis · phase 3 —Ixe Long-Term Extension NCT01597245 · Phase 3 · Psoriasis · phase 3 1.1%Q2W NCT01597245 · Phase 3 · Psoriasis · phase 3 —Q4W NCT01597245 · Phase 3 · Psoriasis · phase 3 1.4%Q4W NCT01597245 · Phase 3 · Psoriasis · phase 3 —Q4W NCT01597245 · Phase 3 · Psoriasis · phase 3 —Q4W NCT01597245 · Phase 3 · Psoriasis · phase 3 —ETN/IXEQ4W (Maintenance Period) NCT03073200 · Phase 3 —ETN/IXEQ4W/IXEQ4W (Extension Perio NCT03073200 · Phase 3 —IXEQ4W (Double-Blinded Treatment P NCT03073200 · Phase 3 —IXEQ4W (Randomized Withdrawal Peri NCT03073200 · Phase 3 —IXEQ4W/IXEQ4W (Maintenance Period) NCT03073200 · Phase 3 —IXEQ4W/IXEQ4W/IXEQ4W (Extension Pe NCT03073200 · Phase 3 —IXEQ4W_Re-Treatment (Randomized Wi NCT03073200 · Phase 3 —PBO/IXEQ4W (Maintenance Period) NCT03073200 · Phase 3 —PBO/IXEQ4W/IXEQ4W (Extension Perio NCT03073200 · Phase 3 —Q2W NCT01695239 · Phase 3 —Q4W NCT01695239 · Phase 3 2.9%Q2W NCT01695239 · Phase 3 1.9%Q4W NCT01695239 · Phase 3 —Q2W NCT01695239 · Phase 3 —Q4W NCT01695239 · Phase 3 2.1%80 mg every 2 weeks NCT01646177 · Phase 3 2.3%80 mg every 4 weeks NCT01646177 · Phase 3 —Ixekizumab - Active PsA NCT05855967 · Phase 4 · registry result, not featured evidence —Ixekizumab - PsO With no Active Ps NCT05855967 · Phase 4 · registry result, not featured evidence —Q2W/Q4W NCT05855967 · Phase 4 · registry result, not featured evidence —Q4W NCT05855967 · Phase 4 · registry result, not featured evidence 20%Ixekizumab - Erythrodermic Psorias NCT03942042 · Phase 4 · registry result, not featured evidence 0%Ixekizumab - Generalized Pustular NCT03942042 · Phase 4 · registry result, not featured evidence 2.9% NCT03573323 · Phase 4 · registry result, not featured evidence —80 mg Q2W NCT03364309 · Phase 3 · registry result, not featured evidence —80 mg Q2W NCT03364309 · Phase 3 · registry result, not featured evidence —80 mg Q2W NCT03364309 · Phase 3 · registry result, not featured evidence —80 mg Q2W NCT03364309 · Phase 3 · registry result, not featured evidence —80 mg Q2W NCT03364309 · Phase 3 · registry result, not featured evidence —80 mg Q2W NCT03364309 · Phase 3 · registry result, not featured evidence 0.6%80 mg Q2W NCT03364309 · Phase 3 · registry result, not featured evidence —80 mg Q4W NCT03364309 · Phase 3 · registry result, not featured evidence —80 mg Q4W NCT03364309 · Phase 3 · registry result, not featured evidence —80 mg Q4W NCT03364309 · Phase 3 · registry result, not featured evidence —80 mg Q4W NCT03364309 · Phase 3 · registry result, not featured evidence —80 mg Q4W NCT03364309 · Phase 3 · registry result, not featured evidence —80 mg Q4W NCT03364309 · Phase 3 · registry result, not featured evidence 0%80 mg Q4W NCT03364309 · Phase 3 · registry result, not featured evidence —80 mg Q2W NCT02718898 · Phase 3 · registry result, not featured evidence 3.7%Ixekizumab NCT02634801 · Phase 3 · registry result, not featured evidence —Ixekizumab-Extension Period NCT02634801 · Phase 3 · registry result, not featured evidence —Ixekizumab-Treatment Period NCT02634801 · Phase 3 · registry result, not featured evidence 1.5%Ixekizumab NCT02561806 · Phase 3 · registry result, not featured evidence —Ixekizumab - Induction NCT02561806 · Phase 3 · registry result, not featured evidence —Ixekizumab - Maintenance NCT02561806 · Phase 3 · registry result, not featured evidence —Ixekizumab - Post Treatment Follow NCT02561806 · Phase 3 · registry result, not featured evidence 1.1%80 mg NCT01624233 · Phase 3 · registry result, not featured evidence —80 mg NCT01624233 · Phase 3 · registry result, not featured evidence —80 mg NCT01624233 · Phase 3 · registry result, not featured evidence 2.8%80 mg Q2W NCT02513550 · Phase 3 · registry result, not featured evidence —80 mg Q2W NCT02513550 · Phase 3 · registry result, not featured evidence —80 mg Q2W NCT02513550 · Phase 3 · registry result, not featured evidence 1.6%80 mg Q4W NCT02513550 · Phase 3 · registry result, not featured evidence —80 mg Q4W NCT02513550 · Phase 3 · registry result, not featured evidence 4.2%80 mg Q4W/Q2W NCT02513550 · Phase 3 · registry result, not featured evidence —80 mg Q4W/Q2W NCT02513550 · Phase 3 · registry result, not featured evidence —80 mg Q4W/Q2W NCT02513550 · Phase 3 · registry result, not featured evidence —80 mg Q4W NCT02513550 · Phase 3 · registry result, not featured evidence —80 mg Q4W NCT02387801 · Phase 3 · registry result, not featured evidence —Q2W NCT02387801 · Phase 3 · registry result, not featured evidence —Q2W NCT02387801 · Phase 3 · registry result, not featured evidence —Q4W NCT02387801 · Phase 3 · registry result, not featured evidence —Q4W NCT02387801 · Phase 3 · registry result, not featured evidence —80 mg NCT01777191 · Phase 3 · registry result, not featured evidence 1%80 mg NCT01777191 · Phase 3 · registry result, not featured evidence —80 mg NCT01777191 · Phase 3 · registry result, not featured evidence 2%80 mg NCT01777191 · Phase 3 · registry result, not featured evidence —80 mg NCT01777191 · Phase 3 · registry result, not featured evidence 0%150 mg NCT01107457 · Phase 2 · registry result, not featured evidence 0%75 mg NCT01107457 · Phase 2 · registry result, not featured evidence 3.3%25 mg NCT01107457 · Phase 2 · registry result, not featured evidence 7.1%10 mg NCT01107457 · Phase 2 · registry result, not featured evidence —80mg Q2W Multiple Dose NCT03073213 · Phase 1 · registry result, not featured evidence —80mg Q4W Multiple Dose NCT03073213 · Phase 1 · registry result, not featured evidence —Single Dose NCT03073213 · Phase 1 · registry result, not featured evidence — NCT02993471 · Phase 1 · registry result, not featured evidence · combination | —Q2Wb NCT03390101 · Phase 3 · monotherapy · Psoriasis · phase 3 show 4 more results—Q4W NCT03390101 · Phase 3 · monotherapy · Psoriasis · phase 3 —120 mg NCT02762994 · Phase 2 · registry result, not featured evidence —80 mg NCT02762994 · Phase 2 · registry result, not featured evidence —40 mg NCT02762994 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 12.7%Ixe Long-Term Extensiona NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 show 93 more results1.6%Q2W NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 2.8%Q4W NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 3.2%Q4W NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 10.3%Q4W NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 4.8%Q12W NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 6.1%Q4W NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 3.8%Placebo Long-Term Extension NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 6.1%Q4W NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 4.8%Q4W NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 12.5%Total Ixe Long-Term Extension NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 4.5%Q4W NCT01597245 · Phase 3 · Psoriasis · phase 3 10.9%Ixe Long-Term Extension NCT01597245 · Phase 3 · Psoriasis · phase 3 1.4%Q2W NCT01597245 · Phase 3 · Psoriasis · phase 3 4.1%Q4W NCT01597245 · Phase 3 · Psoriasis · phase 3 2.3%Q4W NCT01597245 · Phase 3 · Psoriasis · phase 3 5.3%Q4W NCT01597245 · Phase 3 · Psoriasis · phase 3 8.4%Q4W NCT01597245 · Phase 3 · Psoriasis · phase 3 3.6%ETN/IXEQ4W (Maintenance Period) NCT03073200 · Phase 3 0%ETN/IXEQ4W/IXEQ4W (Extension Perio NCT03073200 · Phase 3 0.9%IXEQ4W (Double-Blinded Treatment P NCT03073200 · Phase 3 8.8%IXEQ4W (Randomized Withdrawal Peri NCT03073200 · Phase 3 6.2%IXEQ4W/IXEQ4W (Maintenance Period) NCT03073200 · Phase 3 2.9%IXEQ4W/IXEQ4W/IXEQ4W (Extension Pe NCT03073200 · Phase 3 0%IXEQ4W_Re-Treatment (Randomized Wi NCT03073200 · Phase 3 5.7%PBO/IXEQ4W (Maintenance Period) NCT03073200 · Phase 3 0%PBO/IXEQ4W/IXEQ4W (Extension Perio NCT03073200 · Phase 3 0%Q2W NCT01695239 · Phase 3 0%Q4W NCT01695239 · Phase 3 10.4%Q2W NCT01695239 · Phase 3 15%Q4W NCT01695239 · Phase 3 5.6%Q2W NCT01695239 · Phase 3 2.9%Q4W NCT01695239 · Phase 3 2.3%80 mg every 2 weeks NCT01646177 · Phase 3 1.6%80 mg every 4 weeks NCT01646177 · Phase 3 —Ixekizumab - Active PsA NCT05855967 · Phase 4 · registry result, not featured evidence —Ixekizumab - PsO With no Active Ps NCT05855967 · Phase 4 · registry result, not featured evidence 0.5%Q2W/Q4W NCT05855967 · Phase 4 · registry result, not featured evidence 0%Q4W NCT05855967 · Phase 4 · registry result, not featured evidence —Ixekizumab - Erythrodermic Psorias NCT03942042 · Phase 4 · registry result, not featured evidence —Ixekizumab - Generalized Pustular NCT03942042 · Phase 4 · registry result, not featured evidence 3.5% NCT03573323 · Phase 4 · registry result, not featured evidence 4.3%80 mg Q2W NCT03364309 · Phase 3 · registry result, not featured evidence 2%80 mg Q2W NCT03364309 · Phase 3 · registry result, not featured evidence 2%80 mg Q2W NCT03364309 · Phase 3 · registry result, not featured evidence 0%80 mg Q2W NCT03364309 · Phase 3 · registry result, not featured evidence 4.4%80 mg Q2W NCT03364309 · Phase 3 · registry result, not featured evidence 0%80 mg Q2W NCT03364309 · Phase 3 · registry result, not featured evidence 0.6%80 mg Q2W NCT03364309 · Phase 3 · registry result, not featured evidence 0%80 mg Q4W NCT03364309 · Phase 3 · registry result, not featured evidence 5.4%80 mg Q4W NCT03364309 · Phase 3 · registry result, not featured evidence 2.1%80 mg Q4W NCT03364309 · Phase 3 · registry result, not featured evidence 0%80 mg Q4W NCT03364309 · Phase 3 · registry result, not featured evidence 2.3%80 mg Q4W NCT03364309 · Phase 3 · registry result, not featured evidence 1.9%80 mg Q4W NCT03364309 · Phase 3 · registry result, not featured evidence 1.1%80 mg Q4W NCT03364309 · Phase 3 · registry result, not featured evidence 0%80 mg Q2W NCT02718898 · Phase 3 · registry result, not featured evidence —Ixekizumab NCT02634801 · Phase 3 · registry result, not featured evidence 6.3%Ixekizumab-Extension Period NCT02634801 · Phase 3 · registry result, not featured evidence 1.9%Ixekizumab-Treatment Period NCT02634801 · Phase 3 · registry result, not featured evidence —Ixekizumab NCT02561806 · Phase 3 · registry result, not featured evidence 1.5%Ixekizumab - Induction NCT02561806 · Phase 3 · registry result, not featured evidence 5.3%Ixekizumab - Maintenance NCT02561806 · Phase 3 · registry result, not featured evidence 0%Ixekizumab - Post Treatment Follow NCT02561806 · Phase 3 · registry result, not featured evidence —80 mg NCT01624233 · Phase 3 · registry result, not featured evidence 4.4%80 mg NCT01624233 · Phase 3 · registry result, not featured evidence 11.3%80 mg NCT01624233 · Phase 3 · registry result, not featured evidence —80 mg Q2W NCT02513550 · Phase 3 · registry result, not featured evidence 5.3%80 mg Q2W NCT02513550 · Phase 3 · registry result, not featured evidence 0%80 mg Q2W NCT02513550 · Phase 3 · registry result, not featured evidence —80 mg Q4W NCT02513550 · Phase 3 · registry result, not featured evidence 0%80 mg Q4W NCT02513550 · Phase 3 · registry result, not featured evidence —80 mg Q4W/Q2W NCT02513550 · Phase 3 · registry result, not featured evidence 5.2%80 mg Q4W/Q2W NCT02513550 · Phase 3 · registry result, not featured evidence 20%80 mg Q4W/Q2W NCT02513550 · Phase 3 · registry result, not featured evidence 5.2%80 mg Q4W NCT02513550 · Phase 3 · registry result, not featured evidence 0%80 mg Q4W NCT02387801 · Phase 3 · registry result, not featured evidence —Q2W NCT02387801 · Phase 3 · registry result, not featured evidence 0%Q2W NCT02387801 · Phase 3 · registry result, not featured evidence —Q4W NCT02387801 · Phase 3 · registry result, not featured evidence 0%Q4W NCT02387801 · Phase 3 · registry result, not featured evidence 4.9%80 mg NCT01777191 · Phase 3 · registry result, not featured evidence —80 mg NCT01777191 · Phase 3 · registry result, not featured evidence 3.9%80 mg NCT01777191 · Phase 3 · registry result, not featured evidence —80 mg NCT01777191 · Phase 3 · registry result, not featured evidence 2.9%80 mg NCT01777191 · Phase 3 · registry result, not featured evidence 0%150 mg NCT01107457 · Phase 2 · registry result, not featured evidence 0%75 mg NCT01107457 · Phase 2 · registry result, not featured evidence 3.3%25 mg NCT01107457 · Phase 2 · registry result, not featured evidence 3.6%10 mg NCT01107457 · Phase 2 · registry result, not featured evidence 7.1%80mg Q2W Multiple Dose NCT03073213 · Phase 1 · registry result, not featured evidence 0%80mg Q4W Multiple Dose NCT03073213 · Phase 1 · registry result, not featured evidence 0%Single Dose NCT03073213 · Phase 1 · registry result, not featured evidence 0% NCT02993471 · Phase 1 · registry result, not featured evidence · combination | 0%Q2Wb NCT03390101 · Phase 3 · monotherapy · Psoriasis · phase 3 show 4 more results1.2%Q4W NCT03390101 · Phase 3 · monotherapy · Psoriasis · phase 3 0%120 mg NCT02762994 · Phase 2 · registry result, not featured evidence 0%80 mg NCT02762994 · Phase 2 · registry result, not featured evidence 0%40 mg NCT02762994 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | a nasopharyngitis 16.9% (placebo 11.5%) upper respiratory tract infection 8.4% (placebo 8%) arthralgia 5.1% (placebo 2.7%) NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 show 79 more resultsQ2W nasopharyngitis 11.3% (placebo 11.5%) injection site reaction 9.7% (placebo 0.9%) injection site erythema 6.5% (placebo 0%) NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 Q4W nasopharyngitis 10.4% (placebo 11.5%) injection site reaction 6.3% (placebo 0.9%) upper respiratory tract infection 4.6% (placebo 8%) NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 Q4W nasopharyngitis 10.6% (placebo 11.5%) upper respiratory tract infection 5.2% (placebo 8%) injection site reaction 3.7% (placebo 0.9%) NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 Q4W nasopharyngitis 24.4% (placebo 11.5%) arthralgia 10.3% (placebo 2.7%) upper respiratory tract infection 10.3% (placebo 8%) NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 Q12W nasopharyngitis 18.1% (placebo 11.5%) upper respiratory tract infection 8.8% (placebo 8%) headache 7% (placebo 2.2%) NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 Q4W nasopharyngitis 22.3% (placebo 11.5%) upper respiratory tract infection 7.9% (placebo 8%) arthralgia 5.7% (placebo 2.7%) NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 nasopharyngitis 15.4% (placebo 11.5%) influenza 7.7% (placebo 1.8%) upper respiratory tract infection 7.7% (placebo 8%) NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 Q4W nasopharyngitis 19.7% (placebo 11.5%) upper respiratory tract infection 13.6% (placebo 8%) injection site reaction 9.2% (placebo 0.9%) NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 Q4W nasopharyngitis 17.7% (placebo 11.5%) back pain 9.7% (placebo 3.1%) upper respiratory tract infection 6.5% (placebo 8%) NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 nasopharyngitis 16.6% (placebo 11.5%) upper respiratory tract infection 8.3% (placebo 8%) arthralgia 5% (placebo 2.7%) NCT01474512 · Phase 3 · combination · Psoriasis · phase 3 Q4W nasopharyngitis 17.5% (placebo 14.4%) upper respiratory tract infection 10.5% (placebo 6.1%) injection site reaction 10% (placebo 0.8%) NCT01597245 · Phase 3 · Psoriasis · phase 3 nasopharyngitis 12.8% (placebo 14.4%) upper respiratory tract infection 11% (placebo 6.1%) arthralgia 4.9% (placebo 6.1%) NCT01597245 · Phase 3 · Psoriasis · phase 3 Q2W injection site reaction 11.4% (placebo 0.8%) nasopharyngitis 9.7% (placebo 14.4%) upper respiratory tract infection 5.7% (placebo 6.1%) NCT01597245 · Phase 3 · Psoriasis · phase 3 Q4W nasopharyngitis 16.3% (placebo 14.4%) upper respiratory tract infection 14.3% (placebo 6.1%) headache 8.2% (placebo 3.8%) NCT01597245 · Phase 3 · Psoriasis · phase 3 Q4W nasopharyngitis 8.1% (placebo 14.4%) injection site reaction 5.5% (placebo 0.8%) headache 4.9% (placebo 3.8%) NCT01597245 · Phase 3 · Psoriasis · phase 3 Q4W nasopharyngitis 16% (placebo 14.4%) upper respiratory tract infection 9.3% (placebo 6.1%) vulvovaginal candidiasis 9.1% (placebo 0%) NCT01597245 · Phase 3 · Psoriasis · phase 3 Q4W nasopharyngitis 18.7% (placebo 14.4%) upper respiratory tract infection 12.9% (placebo 6.1%) injection site reaction 6.5% (placebo 0.8%) NCT01597245 · Phase 3 · Psoriasis · phase 3 nasopharyngitis 14.3% (placebo 7.1%) pharyngitis 14.3% (placebo 0%) tonsillitis 14.3% (placebo 3.6%) NCT03073200 · Phase 3 acne 11.1% (placebo 1.8%) headache 11.1% (placebo 1.8%) influenza 11.1% (placebo 0%) NCT03073200 · Phase 3 nasopharyngitis 11.3% (placebo 7.1%) headache 10.4% (placebo 1.8%) injection site reaction 9.6% (placebo 0%) NCT03073200 · Phase 3 nasopharyngitis 32.4% (placebo 7.1%) tonsillitis 8.8% (placebo 3.6%) viral upper respiratory tract infection 8.8% (placebo 0%) NCT03073200 · Phase 3 injection site reaction 17.7% (placebo 0%) nasopharyngitis 14.2% (placebo 7.1%) upper respiratory tract infection 11.5% (placebo 7.1%) NCT03073200 · Phase 3 upper respiratory tract infection 16.2% (placebo 7.1%) nasopharyngitis 11.8% (placebo 7.1%) headache 8.8% (placebo 1.8%) NCT03073200 · Phase 3 diarrhoea 6.1% (placebo 1.8%) nasopharyngitis 6.1% (placebo 7.1%) pharyngitis 6.1% (placebo 0%) NCT03073200 · Phase 3 injection site reaction 15.1% (placebo 0%) nasopharyngitis 13.2% (placebo 7.1%) upper respiratory tract infection 9.4% (placebo 7.1%) NCT03073200 · Phase 3 upper respiratory tract infection 29.4% (placebo 7.1%) bronchitis 8.8% (placebo 0%) pharyngitis 8.8% (placebo 0%) NCT03073200 · Phase 3 Q2W back pain 0% (placebo 0%) bronchitis 0% (placebo 2.8%) injection site erythema 0% (placebo 0%) NCT01695239 · Phase 3 Q4W back pain 0% (placebo 0%) bronchitis 0% (placebo 2.8%) injection site erythema 0% (placebo 0%) NCT01695239 · Phase 3 Q2W viral upper respiratory tract infection 11.5% (placebo 4.7%) upper respiratory tract infection 9.8% (placebo 6.6%) injection site reaction 7.1% (placebo 0%) NCT01695239 · Phase 3 Q4W upper respiratory tract infection 11.2% (placebo 6.6%) viral upper respiratory tract infection 11.2% (placebo 4.7%) injection site reaction 6.4% (placebo 0%) NCT01695239 · Phase 3 Q2W injection site reaction 12.1% (placebo 0%) injection site erythema 6.5% (placebo 0%) viral upper respiratory tract infection 5.6% (placebo 4.7%) NCT01695239 · Phase 3 Q4W injection site reaction 15.7% (placebo 0%) injection site erythema 12.7% (placebo 0%) bronchitis 2.9% (placebo 2.8%) NCT01695239 · Phase 3 80 mg every 2 weeks injection site reaction 9.6% (placebo 1.6%) nasopharyngitis 6.8% (placebo 5.7%) headache 4.2% (placebo 2.6%) NCT01646177 · Phase 3 80 mg every 4 weeks injection site reaction 11.3% (placebo 1.6%) nasopharyngitis 7.6% (placebo 5.7%) headache 4.2% (placebo 2.6%) NCT01646177 · Phase 3 Q2W/Q4W latent tuberculosis 8.6% pyrexia 8.6% injection site erythema 1.9% NCT05855967 · Phase 4 · registry result, not featured evidence Q4W latent tuberculosis 9.8% urinary tract infection 4.9% c-reactive protein increased 2.4% NCT05855967 · Phase 4 · registry result, not featured evidence injection site reaction 9.4% upper respiratory tract infection 7.7% nasopharyngitis 6.6% NCT03573323 · Phase 4 · registry result, not featured evidence 80 mg Q2W blood glucose increased 17.4% (placebo 6.3%) folliculitis 13% (placebo 5.1%) hepatic function abnormal 13% (placebo 5.1%) NCT03364309 · Phase 3 · registry result, not featured evidence 80 mg Q2W upper respiratory tract infection 31% (placebo 27.8%) injection site reaction 17% (placebo 10.1%) tinea pedis 10% (placebo 7.6%) NCT03364309 · Phase 3 · registry result, not featured evidence 80 mg Q2W upper respiratory tract infection 12% (placebo 27.8%) oropharyngeal pain 10% (placebo 2.5%) blood triglycerides increased 8% (placebo 0%) NCT03364309 · Phase 3 · registry result, not featured evidence 80 mg Q2W alopecia 10% (placebo 0%) blood immunoglobulin a increased 10% (placebo 1.3%) blood urine present 10% (placebo 6.3%) NCT03364309 · Phase 3 · registry result, not featured evidence 80 mg Q2W upper respiratory tract infection 20% (placebo 27.8%) injection site reaction 11.1% (placebo 10.1%) oropharyngeal pain 11.1% (placebo 2.5%) NCT03364309 · Phase 3 · registry result, not featured evidence 80 mg Q2W alopecia 0% (placebo 0%) arthralgia 0% (placebo 0%) blood glucose decreased 0% (placebo 0%) NCT03364309 · Phase 3 · registry result, not featured evidence 80 mg Q2W upper respiratory tract infection 15.9% (placebo 27.8%) injection site reaction 10.8% (placebo 10.1%) urticaria 5.7% (placebo 11.4%) NCT03364309 · Phase 3 · registry result, not featured evidence 80 mg Q4W upper respiratory tract infection 25.8% (placebo 27.8%) blood urine present 12.9% (placebo 6.3%) tinea pedis 12.9% (placebo 7.6%) NCT03364309 · Phase 3 · registry result, not featured evidence 80 mg Q4W upper respiratory tract infection 27.2% (placebo 27.8%) injection site reaction 18.5% (placebo 10.1%) tinea pedis 12% (placebo 7.6%) NCT03364309 · Phase 3 · registry result, not featured evidence 80 mg Q4W upper respiratory tract infection 14.9% (placebo 27.8%) oropharyngeal pain 8.5% (placebo 2.5%) pruritus 8.5% (placebo 2.5%) NCT03364309 · Phase 3 · registry result, not featured evidence 80 mg Q4W tonsillitis 28.6% (placebo 0%) upper respiratory tract infection 28.6% (placebo 27.8%) dermatitis allergic 14.3% (placebo 5.1%) NCT03364309 · Phase 3 · registry result, not featured evidence 80 mg Q4W upper respiratory tract infection 16.3% (placebo 27.8%) injection site reaction 7% (placebo 10.1%) rhinitis 7% (placebo 1.3%) NCT03364309 · Phase 3 · registry result, not featured evidence 80 mg Q4W hepatic function abnormal 1.3% (placebo 5.1%) blood glucose increased 1.1% (placebo 6.3%) upper respiratory tract infection 1.1% (placebo 27.8%) NCT03364309 · Phase 3 · registry result, not featured evidence 80 mg Q4W upper respiratory tract infection 14.4% (placebo 27.8%) injection site reaction 7.5% (placebo 10.1%) hepatic function abnormal 5.7% (placebo 5.1%) NCT03364309 · Phase 3 · registry result, not featured evidence 80 mg Q2W upper respiratory tract infection 16% (placebo 6.8%) injection site reaction 6.7% (placebo 0%) headache 4% (placebo 5.4%) NCT02718898 · Phase 3 · registry result, not featured evidence nasopharyngitis 37.5% back pain 6.3% bronchitis 4.2% NCT02634801 · Phase 3 · registry result, not featured evidence nasopharyngitis 37% headache 13% injection site reaction 13% NCT02634801 · Phase 3 · registry result, not featured evidence nasopharyngitis 17% injection site erythema 7.4% headache 5.2% NCT02561806 · Phase 3 · registry result, not featured evidence nasopharyngitis 27.5% headache 7.6% arthralgia 6.1% NCT02561806 · Phase 3 · registry result, not featured evidence 80 mg viral upper respiratory tract infection 39.6% eczema 12.1% injection site reaction 8.8% NCT01624233 · Phase 3 · registry result, not featured evidence 80 mg viral upper respiratory tract infection 20% eczema 12.5% eczema asteatotic 11.3% NCT01624233 · Phase 3 · registry result, not featured evidence 80 mg Q2W viral upper respiratory tract infection 12% upper respiratory tract infection 11.3% injection site reaction 8% NCT02513550 · Phase 3 · registry result, not featured evidence 80 mg Q2W viral upper respiratory tract infection 37.5% vaginal infection 25% injection site erythema 12.5% NCT02513550 · Phase 3 · registry result, not featured evidence 80 mg Q4W upper respiratory tract infection 22.2% alanine aminotransferase increased 11.1% aspartate aminotransferase increased 11.1% NCT02513550 · Phase 3 · registry result, not featured evidence 80 mg Q4W/Q2W viral upper respiratory tract infection 17.3% upper respiratory tract infection 12.7% headache 5.2% NCT02513550 · Phase 3 · registry result, not featured evidence 80 mg Q4W/Q2W arthralgia 20% benign bone neoplasm 20% blood glucose increased 20% NCT02513550 · Phase 3 · registry result, not featured evidence 80 mg Q4W upper respiratory tract infection 14.8% viral upper respiratory tract infection 13.2% injection site reaction 5.8% NCT02513550 · Phase 3 · registry result, not featured evidence 80 mg Q4W upper respiratory tract infection 33.3% biopsy breast 16.7% influenza 16.7% NCT02387801 · Phase 3 · registry result, not featured evidence Q2W arthralgia 33.3% acne 16.7% hyperhidrosis 16.7% NCT02387801 · Phase 3 · registry result, not featured evidence Q4W biopsy prostate 33.3% injection site urticaria 33.3% hordeolum 16.7% NCT02387801 · Phase 3 · registry result, not featured evidence 80 mg upper respiratory tract infection 8.6% injection site reaction 4.3% NCT01777191 · Phase 3 · registry result, not featured evidence 80 mg injection site reaction 4.9% upper respiratory tract infection 4.9% NCT01777191 · Phase 3 · registry result, not featured evidence 80 mg injection site reaction 7.8% upper respiratory tract infection 3.9% NCT01777191 · Phase 3 · registry result, not featured evidence 150 mg nasopharyngitis 14.3% (placebo 18.5%) dermatitis contact 7.1% (placebo 0%) dry skin 7.1% (placebo 0%) NCT01107457 · Phase 2 · registry result, not featured evidence 75 mg nasopharyngitis 10.3% (placebo 18.5%) cough 6.9% (placebo 0%) dizziness 6.9% (placebo 0%) NCT01107457 · Phase 2 · registry result, not featured evidence 25 mg headache 13.3% (placebo 3.7%) injection site reaction 10% (placebo 0%) nasopharyngitis 10% (placebo 18.5%) NCT01107457 · Phase 2 · registry result, not featured evidence 10 mg headache 14.3% (placebo 3.7%) nasopharyngitis 10.7% (placebo 18.5%) dizziness 7.1% (placebo 0%) NCT01107457 · Phase 2 · registry result, not featured evidence 80mg Q2W Multiple Dose pruritus 42.9% upper respiratory tract infection 35.7% diarrhoea 21.4% NCT03073213 · Phase 1 · registry result, not featured evidence 80mg Q4W Multiple Dose upper respiratory tract infection 20% arthralgia 13.3% diarrhoea 13.3% NCT03073213 · Phase 1 · registry result, not featured evidence Single Dose pruritus 41.7% protein urine present 33.3% flatulence 25% NCT03073213 · Phase 1 · registry result, not featured evidence alopecia 3.7% arthralgia 3.7% back pain 3.7% NCT02993471 · Phase 1 · registry result, not featured evidence · combination | Q2Wb hyperbilirubinemia 4.7% (placebo 2.3%) neutropenia 3.5% (placebo 0%) alanine aminotransferase increased 1.2% (placebo 0%) NCT03390101 · Phase 3 · monotherapy · Psoriasis · phase 3 show 4 more resultsQ4W hyperglycaemia 3.6% (placebo 0%) hyperbilirubinemia 2.4% (placebo 2.3%) leukopenia 2.4% (placebo 0%) NCT03390101 · Phase 3 · monotherapy · Psoriasis · phase 3 120 mg arterial bp increased 10.7% (placebo 0%) arvi 3.6% (placebo 3.6%) flu-like symptoms 3.6% (placebo 0%) NCT02762994 · Phase 2 · registry result, not featured evidence 80 mg ggt increased 10% (placebo 7.1%) arterial bp increased 6.7% (placebo 0%) neutropenia 6.7% (placebo 3.6%) NCT02762994 · Phase 2 · registry result, not featured evidence 40 mg neutropenia 12.9% (placebo 3.6%) arvi 9.7% (placebo 3.6%) conjuctivitis 3.2% (placebo 0%) NCT02762994 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 76 of these studies.
- bPopulation comparability has not been reviewed for 3 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
ixekizumab
show 21 more results
show 10 more results
show 1 more result
show 1 more result
show 1 more result
show 13 more results
show 15 more results
show 3 more results
show 14 more results
show 7 more results
show 10 more results
show 12 more results
+ 105 further endpoints in the CSV export.
netakimab
show 2 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ixekizumab's landscape · netakimab's landscape